He is going to buy Valeant for sure. I'm a buyer tomorrow, and I hoe it will remain under $35. This man just lost a Billion in a day, and he intends to recover it rather sooooooooooooon.
I would say so as well.....The man just sold millions of shares of another company to buy this stock possibly tomorrow....... It will print $40 tomorrow for sure, or heck maybe tonight within an hour from now.
Let's start with the most ironic of options: Valeant Pharmaceuticals (VRX - Get Report) . Given Valeant's myriad accounting issues and mountain of debt at risk of default, Saunders could -- and should -- probably wait to pick up Valeant's best assets in a fire sale or bankruptcy. Think the Salix drugs which treat stomach disorders.
Allergan might be interested in acquiring Valeant'sBausch & Lomb eye care unit. [Bill Ackman has said Valeant could sell Bausch & Lomb to raise money].
A position, does this make any sense? " Although Hempton has covered some of the short he still has a position and he states why he thinks the stock is going to zero."
I had bought Facebook shares when they went Public on that doom Friday. It was so ridiculous I found out how much I paid for my 500 shares on Monday due to the glitch Nasdaq had. It was $40.93 a share, and I kept buying to average out till it hit bottom at $16 a share. YES, $16 folks. I bailed out then due to the negativity surrounding FB with a huge loss, it made so sick seeing how much it is now. So, my advice to y'all is don't make the same mistake I have made, and I think that Twitter still hasn't bottom out yet, but keep buying if it goes down from the current level because I can see the same scenario is happening again here, and we all know Twitter isn't going anywhere and people are going to use it, and I'm sure the company will find ways to generate revenue. The bottom line, DO NOT SELL.
According to Moussatos, Relypsa could sell for $52 per share, or $2.3 billion based on shares outstanding.
Moussatos also noted that Regulus, a drug company that focuses on a wide variety of diseases, could sell for around $48 per share, or $2.5 billion based on shares outstanding, and Intercept Pharmaceuticals, a drug company that focuses on liver drugs, could go for as much as $423 per share, or $10.3 billion.
I can't sleep. Got in on Friday 1k @ 27. Risk vs. Reward is huge here, and I'm taking my chances toward a huge R E W A R D. I bought 2k shares on Friday, 1k for SRPT, and the second 1k VRX. I'm dreaming BIG, but unable to sleep :)